Fish oil, melatonin and vitamin e attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2, 3,6- tetrahydropyridine

Metabolic Brain Disease

Volumn 28, Issue 4, 2013, Pages 705-709

  Ortiz, Genaro Gabriel ^a   Pacheco Moisés, Fermín P ^b   Gómez Rodríguez, Víctor M ^a   González Renovato, Erika D ^a   Torres Sánchez, Erandhis D ^a   Ramírez Anguiano, Ana C ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Cyclooxygenase 2; Fish oil; Melatonin; Oxidative stress; Vitamin E

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; CYCLOOXYGENASE 2; FISH OIL; LIPID PEROXIDE; MELATONIN; NITRATE; NITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; HOMOGENATE; MALE; MESENCEPHALON; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS;

ANIMALIA; MUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CYCLOOXYGENASE 2; FISH OILS; LIPID PEROXIDATION; MELATONIN; MESENCEPHALON; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; VITAMIN E;

EID: 84887247980     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-013-9416-0     Document Type: Article

References (31)

1. Akbar M, Calderon F, Wen Z, Kim HY (2005) Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci USA 102:10858-10863
2. Ballard PA, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35:949-956
3. Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of proteins utilizing the principle of protein-dye binding. Analyt Biochem 72:248-256
4. Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83(6 Suppl):1505S-1519S
5. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O et al (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43:633-645
6. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr et al (2005) Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 22:617-626
7. de Rijk MC, Breteler MM, den Breeijen JH, Launer LJ, Grobbee DE, van der Meché FG et al (1997) Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 54:762-765
8. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H (1991) Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res 32:1325-1332
9. Eling TE, Glasgow WC, Curtis JF, Hubbard WC, Handler JA (1991) Studies on the reduction of endogenously generated prostaglandin G2 by prostaglandin H synthase. J Biol Chem 266:12348-12355
10. Esterbauer H, Cheeseman KH (1990) Determination of aldehydic lipid peroxidation products malonaldehyde and 4-hydroxynonenal. Meth Enzymol 186:407-421
11. Feng Z, Li D, Fung PC, Pei Z, Ramsden DB, Ho SL (2003) COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 14:1927-1929
12. Galano A, Tan DX, Reiter RJ (2011) Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 51:1-16
13. Galano A, Tan DX, Reiter RJ (2013) On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 54:245-257
14. Ghasemi A, Hedayati M, Biabani H (2007) Protein precipitation methods evaluated for determination of serum nitric oxide end products by the Greiss Assay. J Med Sci Res 2:29-32
15. Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y et al (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 81:1084-1091
16. Jackson-Lewis V, Smeyne RJ (2005) MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Neurotox Res 7:193-202
17. Liberatore G, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WJ et al (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat Med 5:1403-1409
18. Maclean CH, Issa AM, Newberry SJ, Mojica WA, Morton SC, Garland RH et al (2005) Effects of omega-3 fatty acids on cognitive function with aging, dementia, and neurological diseases. Evid Rep Technol Assess (Summ) 113:1-4
19. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I et al (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23:563-572
20. Ortiz GG, Crespo-López ME, Morán-Moguel C, García JJ, Reiter RJ, Acuña-Castroviejo D (2001) Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuro Endocrinol Lett 22:101-108
21. Reiter RJ (2003) Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 17:273-285
22. Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martin V, Reiter RJ (2004) Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 36:1-9
23. Salem N Jr, Litman B, Kim HY, Gawrisch K (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36:945-959
24. Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 1:6
25. Schulz JB, Falkenburger BH (2004) Neuronal pathology in Parkinson's disease. Cell Tissue Res 318:135-147
26. Smith WL, Marnett LJ, DeWitt DL (1991) Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 49:153-179
27. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ (1993) Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1:57-60
28. Teismann P, Tieu K, Choi DK et al (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100:5473-5478
29. Wu A, Ying Z, Gomez-Pinilla F (2004) Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 21:1457-1467
30. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C et al (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771
31. Yeleswaram K, McLaughlin LG, Knipe JO, Schabdach D (1997) Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J Pineal Res 22:45-51